Dr. Urte Gayko Ph.D. Net Worth

Dr. Urte Gayko Ph.D. biography

Dr. Urte Gayko Ph.D. is the Head of Regulatory Affairs, Quality Assurance & Safety and Director at Summit Therapeutics Inc.

What is the salary of Dr D?

As the Head of Regulatory Affairs and Quality Assurance & Safety and Director of Summit Therapeutics Inc, the total compensation of Dr D at Summit Therapeutics Inc is $7,759. There are 1 executives at Summit Therapeutics Inc getting paid more, with Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA having the highest compensation of $459,377.

How old is Dr D?

Dr D is 50, he's been the Head of Regulatory Affairs and Quality Assurance & Safety and Director of Summit Therapeutics Inc since . There are 6 older and 1 younger executives at Summit Therapeutics Inc. The oldest executive at Summit Therapeutics Inc is Robert W. Duggan, 77, who is the Co-CEO & Exec. Chairman.

What's Dr D's mailing address?

Urte's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Summit Therapeutics Inc

Over the last 4 years, insiders at Summit Therapeutics Inc have traded over $0 worth of Summit Therapeutics Inc stock and bought 529,946,601 units worth $632,334,967 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh, and Manmeet Singh Soni. On average, Summit Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $751,966,329. The most recent stock trade was executed by Mahkam Zanganeh on 26 March 2024, trading 110,321 units of SMMT stock currently worth $411,497.

What does Summit Therapeutics Inc do?

summit is a uk company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. our strategy focuses on two therapy areas: duchenne muscular dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria c. difficile.

Summit Therapeutics Inc executives and stock owners

Summit Therapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA,
  COO & Director
• Dr. Urte Gayko Ph.D.,
  Head of Regulatory Affairs, Quality Assurance & Safety and Director
• Robert W. Duggan,
  Co-CEO & Exec. Chairman
• Ankur Dhingra,
  Chief Financial Officer
• Divya Chari,
  Head of Global Clinical Operations
• Dr. Anne Heatherington,
  Head of Clinical Devel. and Quantitative Sciences
• Dr. Jonathon Tinsley,
  Chief Scientific Officer of DMD
• Campbell Hair,
  Head of HR?
• Dr. Elaine Stracker,
  Gen. Counsel?
• Dave Gancarz,
  Head of Investor Relations & Corp. Strategy
• Michelle Avery,
  Director of Investor Relations
• Prof. Dame Kay Davies DBE, FRS CBE,
  Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
• Jeff Huber,
  Director
• Camilla Graham,
  Chief Clinical Affairs Officer
• Manmeet Singh Soni,
  COO and CFO
• Mostafa Ronaghi,
  Director
• David Jonathan Powell,
  Chief Scientific Officer
• Luhua Wang,
  Director
• Ujwala Mahatme,
  Director
• Rainer M Erdtmann,
  Director
• Michael Paul Donaldson,
  Chief Financial Officer
• Kenneth A Clark,
  Director
• Jeffrey R Maranian,
  VP Corporate Controller
• Urte Gayko,
  Director
• Mahkam Zanganeh,
  Chief Executive Officer
• Ankur Dhingra,
  Chief Financial Officer
• Robert F. Booth,
  Director
• Yu Xia,
  Director
• Robert W Duggan,
  Co-Chief Executive Officer
• Bhaskar Anand,
  Chief Accounting Officer